ecancer

Lurbinectedin in BRCA 1/2 breast cancer

Dr Judith Balmaña - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

10 Oct 2016

Comment: Ribociclib for breast cancer

Dr Evandro De Azambuja - ‎Jules Bordet Institute, Brussels, Belgium

10 Oct 2016

Treating CNS metastases from breast cancer with a peptide/paclitaxel conjugate

Prof Shou-Ching Tang - Augusta University Cancer Center, Augusta USA

10 Oct 2016

Highlights of ESMO 2016

Dr Andrés Cervantes - ESMO 2016 Scientific Chair

10 Oct 2016

FALCON trial: fulvestrant vs. anastrozole for HR advanced breast cancer

Prof John Robertson - University of Nottingham, Nottingham, UK

8 Oct 2016

Fulvestrant in FALCON trial improves PFS in advanced breast cancer

Dr Matthew Ellis - Washington University in St Louis, USA

8 Oct 2016

Ribociclib improves progression-free survival in advanced breast cancer

Prof Gabriel Hortobagyi - University of Texas MD Anderson Cancer Center, Houston, US

8 Oct 2016

Ribociclib improves PFS for postmenopausal women with hormone receptor-positive breast cancer

Dr Gabriel Hortobagyi - MD Anderson, Houston, USA

8 Oct 2016

Editor's Choice for September 2016

Prof Gordon McVie - Editor in Chief, ecancer

3 Oct 2016

A rationale for early intervention in ER＋ metastatic breast cancer

Dr Hope Rugo - University of San Francisco Cancer Research Institute, San Francisco, USA

1 Sep 2016

Patient advocacy in breast cancer research

Maired Mackenzie - Independent Cancer Patients' Voice, UK

4 Aug 2016

Chemoprevention of breast cancer recurrence

Prof Rob Coleman – The University of Sheffield, Sheffield, UK

4 Aug 2016

More from ecancer